A new frailty assessment tool can aid in the prognosis of urologic cancer patients, its inventors say.
© Akkalak Aiempradit / Shutterstock.com
A new frailty assessment tool can aid in the prognosis of urologic cancer patients, its inventors say.
"It can identify the indications for surgery," said Shingo Hatakeyama, MD, of Hirosaki University in Hirosaki, Japan.
Frailty can be difficult to define, said Dr. Hatakeyama's co-author and colleague at Hirosaki University, Soma Osamu, who presented the findings at the AUA annual meeting in San Francisco. He said previous models have shortcomings.
Fried et al defined frailty as a clinical syndrome in which three or more of the following criteria are present: unintentional weight loss, self-reported exhaustion, weakness in grip strength, slow walking speed, and low physical activity.
But this model may be simplistic, said Osamu. Previous authors have noted that participants in the study performed by Fried and colleagues were younger, less likely to report limitations in activity, less likely to have high blood pressure and stroke, and more likely to perceive their health status as very good or excellent than people those who were ineligible or who refused to participate.
The model proposed by Rockwood et al uses dozens of variables, including changes in everyday activities, head and neck problems, problems getting dressed, poor muscle tone, and myocardial infarction. This approach is too complex, said Osamu.
The authors of the current study created their own index by assessing 605 urologic cancer patients who presented at their office. They chose handgrip strength and gait speed, hemoglobin, albumin, renal function, exhaustion, and depression as their criteria. They selected controls from 2,280 community-dwelling subjects.
They compared frailty variables between pair-matched controls and urologic cancer patients. Using this data, they developed a frailty discriminant score (FDS), and calculated its influence on overall survival.
Next:What the authors foundGait speed, hemoglobin, serum albumin, exhaustion, and depression were significantly worse in patients with all types of cancers than in the pair-matched controls.
Among patients with bladder, upper tract urothelial carcinoma, and renal cell carcinoma, overall survival was significantly shorter in patients with an FDS over 2.30 than in those with a lower score.
Also see: Positive data reported for hydrogel-based urothelial Ca agent
Among patients with prostate cancer, overall survival was significantly shorter in patients with an FDS over 3.30 than in those with a lower score.
Patients with a 0 on the sum of positive components in the Fried criteria scored an FDS of 1.75. A Fried of 1 corresponded to an FDS of 3.28, a Fried of 2 corresponded to an FDS of 3.74, and a Fried of 3 corresponded to an FDS of 6.73. The differences were statistically significant (p<.001).
The tool can help patients and physicians make more informed decisions, Dr. Hatakeyama said. Based on such findings, a surgeon might decide not to perform a procedure, he said.
"We need more data, but it suggests that possibility,” said Dr. Hatakeyama.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.